Close Menu

NEW YORK – Amoy Diagnostics announced Wednesday that it has signed an agreement with Merck KGaA to develop a companion diagnostic test in China to support Merck KGaA's novel MET inhibitor tepotinib (Tepmetko).

Tepotinib is a selective small molecule drug designed to inhibit MET in subjects with non-small cell lung cancer and MET alterations. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.